抗Omicron,有1方法救命!但用錯恐有嚴重致命風險?FDA再給輝瑞開綠燈!比變種病毒更可怕的是?美國住院率飆升,真的如此嗎?家用抗原檢測,10分鐘測出變種,防傳播、防重症!
🎯今日專家 林曉旭博士
🎯數據來源
輝瑞新冠口服藥
1.《科學》期刊:An oral SARS-CoV-2 Mproinhibitor clinical candidatefor the treatment of COVID-19
2. FDA:Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19
3. 美國國家臨床試驗資料庫:STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS
4. 美國國家臨床試驗資料庫:EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
輝瑞新冠新藥和一些藥物服用,可能帶來生命危險
5. FDA說明書:FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVIDTM
默克新冠口服藥
6.FDA說明書:FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR
7.約翰·霍普金斯大學:WEEKLY HOSPITALIZATION TRENDS
美國住院率飆升?
8. CDC:COVID Data Tracker
家用新冠抗原檢測試劑
9. FDA:In Vitro Diagnostics EUAs – Antigen Diagnostic Tests for SARS-CoV-2
10.《國際傳染病學期刊》:Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings
12. 藥物交互作用查詢網站:Interactions with PAXLOVID (nirmatrelvir/ritonavir) and EVUSHELD (tixagevimab/cilgavimab) now available
Discussion about this post